Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost

Novo Nordisk A/S (NYSE:NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.Novo Nordisk stock is charging ahead with explosive momentum. What’s fueling NVO momentum?Wegovy pill showed an average weight loss of about 17% (16.6%) when used along with a reduced-calorie diet and exercise, and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.When looking at the efficacy regardless of whether all patients stayed on treatment, an average weight loss ...